Oura's $625 Million Gamble: Can Wearable Hardware Fuel Clinical AI?
AI-generated image · Bay Street Wire
The acquisition of Counsel Health signals a pivot from passive tracking to active medical intervention, but the leap to diagnostic precision is a steep one.
Oura is attempting to move the goalposts for the smart ring. By acquiring Counsel Health for $625 million, the company is shifting its value proposition from passive biometric monitoring to active clinical intervention.
According to reporting from The Verge, Counsel Health describes itself as an "AI-native primary care company." The startup utilizes an AI chatbot to deliver health insights based on wearable data, which can then transition into a consultation with a licensed physician. Oura CEO Tom Hale told Bloomberg that the strategy is to bridge the gap between wearables, clinical AI, and physician access to monitor ongoing conditions or answer specific health questions.
From a hardware perspective, this is a high-stakes pivot. Oura is betting that the biometric data captured by its rings provides enough objective context and trended data for clinicians to make informed medical decisions. As TechCrunch reports, the company intends to focus on three specific pillars: preventative care, acute care for episodic issues, and specialty/chronic care, including cardiometabolic and reproductive health.
**Opinion: The Precision Gap** While the integration of an AI-driven primary care layer is a logical evolution for a health-tracking company, the $625 million price tag raises questions about the underlying hardware's diagnostic capabilities. There is a fundamental difference between tracking a sleep trend and providing the clinical precision required for acute or chronic medical interventions. For this model to scale, the ring's sensors must move beyond "wellness" metrics into the realm of reliable medical data that a physician can trust for prescriptions or referrals.
This aggressive expansion comes at a volatile time for Oura. TechCrunch reports that the company recently postponed a potential IPO valued at up to $2.2 billion, citing market uncertainty. However, the company's financials remain robust; Oura announced quarterly revenue of $533 million, a 153% year-over-year increase, and fiscal year 2026 revenue of approximately $1.75 billion. Following a $900 million funding round in October 2025, Oura's valuation reached $11 billion.
Beyond the financial metrics, Oura is facing increasing hardware competition from rivals like Ultrahuman and RingConn, according to TechCrunch. By absorbing Counsel Health, Oura is attempting to build a "moat" not through sensor specs, but through a vertically integrated healthcare experience.
As part of the deal, Counsel Health CEO Muthu Alagappan will join Oura as the chief clinical AI officer. He will lead a team of 70 employees moving to Oura, including a network of on-demand physicians that Bloomberg reports currently consists of about 50 people.
Oura also plans to keep Counsel Health's platform available to external enterprise partners, such as employers, health systems, and health plans, according to The Verge. The deal is expected to close before the end of 2027, according to TechCrunch.